In vitro surveillance data from across the United States indicate that ∼10%-20% of urinary Escherichia coli isolates from female outpatients are resistant to trimethoprim-sulfamethoxazole (TMP-SMX). Alternative therapies for uncomplicated urinary tract infections in women include fluoroquinolones and nitrofurantoin, but the activities of these agents against TMP-SMX-resistant isolates are rarely reported. Among TMP-SMXresistant urinary E. coli isolates tested in US laboratories from 1998 through 2001, 9.5% (5767 of 60,414) were resistant to ciprofloxacin and 1.9% (1214 of 63,817) were resistant to nitrofurantoin; 10.4% of ciprofloxacinresistant isolates (683 of 6560) were resistant to nitrofurantoin. An association between resistance to fluoroquinolones and nitrofurantoin in E. coli has not been previously reported and warrants further study.
In settings in which the prevalence of trimethoprimsulfamethoxazole (TMP-SMX) resistance is !10%-20%, the currently recommended empiric antimicrobial regimen for treatment of acute uncomplicated bacterial cystitis in otherwise healthy adult nonpregnant women is a 3-day course of double-strength TMP-SMX [1] . Because 75%-90% of uncomplicated urinary tract infection isolates are Escherichia coli [2, 3] , resistance to TMP-SMX among clinical isolates of E. coli is an important indicator of whether TMP-SMX should continue to be used empirically. The prevalence of TMP-SMX resistance among urinary pathogens is now у10%-20% in all regions of the United States [4] [5] [6] , and it appears inevitable that, in the future, empiric treatment of uncomplicated urinary tract infections with TMP-SMX will be replaced by alternative therapies, such as fluoroquinolones or nitro-furantoin [1] . A recent report by Huang and Stafford [7] suggests that many ambulatory care physicians already prescribe fluoroquinolones and nitrofurantoin to treat urinary tract infections in women. Given that a transition in therapy is occurring, or appears imminent, clarity with regard to the current susceptibilities to fluoroquinolones and nitrofurantoin among urinary isolates of E. coli that are resistant to TMP-SMX or other antimicrobial agents is important and of benefit to clinicians.
METHODS
The Surveillance Network (TSN) Database-USA (Focus Technologies) was used as the source of antimicrobial susceptibility testing results for this study. TSN Database-USA assimilates antimicrobial susceptibility testing and patient demographic data from a network of hospitals in the United States [8] . The number of laboratories participating in TSN Database-USA increased from 186 in 1998 to 232 in 1999, 258 in 2000, and 270 in 2001. Laboratories are included in TSN Database-USA on the basis of factors such as the antimicrobial susceptibility testing methods used and the number of beds, patient population, and geographic location of the hospital or hospitals they serve [8] . Antimicrobial susceptibility testing of patient isolates is conducted on site by each participating laboratory as part of routine diagnostic testing. Only data generated using US Food and Drug Administration-approved testing methods and interpretation of MICs according to National Committee for Clinical Laboratory Standards recommendations [9] are included in TSN Database-USA. In addition, a series of quality-control filters (i.e., critical rule sets) are used to screen susceptibility test results for patterns indicative of testing error; suspect results are removed from analysis for laboratory confirmation. The antimicrobial susceptibility testing results included in the current analysis were restricted to the first isolate of E. coli from a clean-catch urine sample submitted per calendar year by unique female outpatients of all ages. Isolates were included in the analysis regardless of the number of antimicrobial agents tested against each individual isolate or the laboratory test method used. Urine specimen sources other than clean-catch (e.g., catheterized urine or catheter-tip cultures) were excluded from the analysis. TMP-SMX, ampicillin, nitrofurantoin, ciprofloxacin, levofloxacin, norfloxacin, ofloxacin, and nalidixic acid susceptibility data were analyzed nationally for 1998-2001.
RESULTS
TMP-SMX, ampicillin, nitrofurantoin, fluoroquinolone, and nalidixic acid susceptibilities for urinary E. coli isolates from female outpatients in 1998-2001 are listed in table 1. Rates of resistance were highest for ampicillin (38.0%) and TMP-SMX (17.5%) and lowest for nitrofurantoin (0.8%). The rate of resistance was 3.5% for nalidixic acid and 1.9%-2.5% for the fluoroquinolones. Annual differences in antimicrobial resistance were minimal: 0.1% for nitrofurantoin, 0.7% for ampicillin, 0.9% for TMP-SMX, and 0.9%-1.5% for the fluoroquinolones and nalidixic acid (data not shown).
Ciprofloxacin susceptibility testing results for E. coli with phenotypes for resistance and isolates with phenotypes for susceptibility to TMP-SMX, ampicillin, and nitrofurantoin are listed in table 2. Similarly, nitrofurantoin susceptibility testing results for E. coli strains that were susceptible or resistant to TMP-SMX, ampicillin, fluoroquinolones, and nalidixic acid are listed in table 3. Rates of nitrofurantoin (0.5%) and ciprofloxacin (0.7%) resistance were similar among TMP-SMXsusceptible isolates. However, among TMP-SMX-resistant isolates, 1.9% were resistant to nitrofurantoin (table 3) and 9.5% were resistant to ciprofloxacin (table 2), a difference of 7.6%. The difference in nitrofurantoin and ciprofloxacin activities was less marked (6.0%) when nitrofurantoin (96.3%) and ciprofloxacin (90.3%) susceptibilities were compared for TMP-SMX-resistant isolates. Among E. coli isolates that were resistant to TMP-SMX, 1.8% were nitrofurantoin intermediate, and 0.1% were ciprofloxacin intermediate. When nitrofurantoinand ciprofloxacin-intermediate isolates were combined with isolates that were resistant to these agents, the magnitude of the difference noted in resistance to nitrofurantoin (3.7%) and ciprofloxacin (9.6%) among TMP-SMX-resistant isolates was 5.9%. Rates of resistance to nitrofurantoin (0.5%) and ciprofloxacin (0.7%) were similar among ampicillin-susceptible isolates. Among ampicillin-resistant isolates, 1.2% were resistant to nitrofurantoin (table 3) , and 4.7% were resistant to ciprofloxacin (table 2), a difference of 3.5%. Again, the difference was slightly less (2.3%) when rates of susceptibility to nitrofurantoin (97.5%) and ciprofloxacin (95.2%) were compared for ampicillin-resistant isolates. Approximately 30% of nitrofurantoin-resistant isolates were ciprofloxacin resistant, a rate antoin susceptibility among fluoroquinolone-resistant isolates by year from 1998 to 2001 were not observed (data not shown).
The overall frequency of isolates that were resistant to both fluoroquinolones and nitrofurantoin was 0.1%-0.2%.
DISCUSSION
In vitro surveillance studies indicate that TMP-SMX resistance among urinary pathogens isolated from female outpatients in the United States is у10%-20% (table 1) [1, 4-6], a threshold above which the Infectious Diseases Society of America recommends consideration of alternative therapies for uncomplicated urinary infections in women [1] . Regional variations in TMP-SMX resistance among E. coli exist across the United States, but TMP-SMX resistance rates have been reported to exceed 10% in all 9 US Bureau of the Census regions [4, 6] . Clinical and microbiologic cure rates for female outpatients with uncomplicated urinary tract infections (cystitis and pyelonephritis) treated with TMP-SMX are lower for pathogens resistant to TMP-SMX than for pathogens susceptible to TMP-SMX [2, [10] [11] [12] [13] [14] . For example, in a study conducted by Raz et al. [10] , microbiologic cure rates for women with uncomplicated urinary tract infections were twice as high among patients infected with TMP-SMX-susceptible pathogens (86% of 333 patients) than among patients infected with TMP-SMXresistant strains (42% of 151 patients) 5-9 days after cessation of TMP-SMX therapy. Clinical cure rates in the same study were similar to microbiologic cure rates for patients infected with TMP-SMX-susceptible (88%) and TMP-SMX-resistant (54%) organisms [10] .
Susceptibility data for TMP-SMX-resistant E. coli or urinary E. coli isolates that are resistant to other antimicrobial agents are not widely available [15] . Only one previously published study has reported the activity of a fluoroquinolone and nitrofurantoin against TMP-SMX-resistant and ampicillin-resistant urinary E. coli isolates [15] . In that report, 0.2% and 2.0% of 689 ampicillin-resistant isolates were resistant to nitrofurantoin and ciprofloxacin, respectively, and 0% and 6.3% of 317 TMP-SMX-resistant isolates, were resistant to nitrofurantoin and ciprofloxacin, respectively. All ciprofloxacin-resistant isolates ( ) were susceptible to nitrofurantoin. The overall n p 20 rates of resistance to nitrofurantoin and ciprofloxacin were 0.1% and 1.2% among 1681 isolates tested [15] . That study [15] concluded that ciprofloxacin resistance was related to resistance to TMP-SMX and ampicillin, an observation confirmed by the present study, but did not report an association between nitrofurantoin resistance and ampicillin resistance, nitrofurantoin resistance and TMP-SMX resistance, or nitrofurantoin resistance and fluoroquinolone resistance, as was found in the present study. The limited sample size of the previously published study [15] likely prevented the observation of the aforementioned rarer phenotypes. The identification of isolates concurrently resistant to fluoroquinolones and nitrofurantoin was novel, but the overall frequency of these isolates was very low (∼0.1%-0.2% of all isolates).
Nitrofurantoin (overall resistance rate, 0.8%) and the fluoroquinolones that we studied (overall resistance rate, 1.9%-2.5%) demonstrated low levels of in vitro resistance, which suggests that both may be used as adequate alternative therapy for female outpatients with uncomplicated urinary tract infections when TMP-SMX cannot be used [1] . The activity of nitrofurantoin and fluoroquinolones against TMP-SMXresistant E. coli may be an important consideration for patient treatment. The present study found that concurrent resistance to ciprofloxacin (9.5%) was ∼5 times more frequent than resistance to nitrofurantoin (1.9%) among TMP-SMX-resistant E. coli. This apparent difference in the activities of nitrofurantoin and ciprofloxacin (7.6%) was lower (6.0%) if suscep- [2] . The similarity in the overall susceptibility of E. coli to nitrofurantoin (98.3%) and ciprofloxacin (97.7%) is of interest because of the different selective factors each agent faces. Nitrofurantoin has a single indication (treatment of acute cystitis), narrow tissue distribution (low or undetectable serum concentrations), narrow spectrum of activity, bactericidal activity against E. coli in urine at therapeutic doses, and limited contact with bacteria outside the urinary tract [16, 17] . In contrast, fluoroquinolones have a wide variety of indications, permeate most body compartments, are broad-spectrum compounds, and are ubiquitously prescribed, factors that are more likely to facilitate the emergence of resistance. Ongoing in vitro surveillance to monitor not only the course of TMP-SMX resistance but also the susceptibilities of nitrofurantoin and fluoroquinolones will be important as these alternative therapies become more widely prescribed [7] . The observed association between resistance to fluoroquinolones and nitrofurantoin in E. coli has not, to our knowledge, been reported elsewhere and warrants further study.
